Novel therapeutic approaches for haemophilia (Q38293116)

1 September 2017

1 reference

title

Novel therapeutic approaches for haemophilia (English)

1 reference

1 September 2017

0 references

S Shetty

1

1 reference

1 September 2017

K Ghosh

series ordinal

2

1 reference

1 September 2017

publication date

18 December 2014

1 reference

1 September 2017

1 reference

1 September 2017

volume

21

1 reference

1 September 2017

issue

2

1 reference

1 September 2017

page(s)

152-161

1 reference

Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database

1 September 2017

cites work

1 reference

Disability in Indian patients with haemophilia

21 January 2018

1 reference

Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A.

21 January 2018

1 reference

PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice

21 January 2018

1 reference

Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)

21 January 2018

1 reference

von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo

21 January 2018

1 reference

Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients.

21 January 2018

1 reference

Reduced clinical severity in a mutationally well-characterized cohort of severe hemophilia with associated thrombophilia

21 January 2018

1 reference

Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children--results of a multicenter studys

21 January 2018

1 reference

Protein C anticoagulant system--anti-inflammatory effects

21 January 2018

1 reference

Interaction of activated protein C with serpins

21 January 2018

1 reference

Tracking structural features leading to resistance of activated protein C to alpha 1-antitrypsin

21 January 2018

1 reference

Activated protein C inhibitor for correction of thrombin generation in hemophilia A blood and plasma1.

21 January 2018

1 reference

Peptidomimetic inhibitors for activated protein C: implications for hemophilia management

21 January 2018

1 reference

Selection of a RNA aptamer that binds to human activated protein C and inhibits its protease function

21 January 2018

1 reference

An exosite-specific ssDNA aptamer inhibits the anticoagulant functions of activated protein C and enhances inhibition by protein C inhibitor

21 January 2018

1 reference

Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A.

21 January 2018

1 reference

Small Peptides Blocking Inhibition of Factor Xa and Tissue Factor-Factor VIIa by Tissue Factor Pathway Inhibitor (TFPI)

21 January 2018

1 reference

Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model

21 January 2018

1 reference

Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor

21 January 2018

1 reference

Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia

21 January 2018

1 reference

Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein

21 January 2018

1 reference

Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia

21 January 2018

1 reference

21 January 2018

FEIBA: mode of action

1 reference

Tissue factor and factor VIIa as therapeutic targets in disorders of hemostasis

21 January 2018

1 reference

A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo

21 January 2018

1 reference

A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa a

21 January 2018

1 reference

Thrombin-activable factor X re-establishes an intrinsic amplification in tenase-deficient plasmas.

21 January 2018

1 reference

Bioengineered factor Xa as a potential new strategy for hemophilia therapy

21 January 2018

1 reference

Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro

21 January 2018

1 reference

A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia

21 January 2018

1 reference

Clinical pharmacological study of a plasma-derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors--phase I trial

21 January 2018

1 reference

Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors--phase I trial: 2nd report

21 January 2018

1 reference

A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics

21 January 2018

1 reference

Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C

21 January 2018

1 reference

Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant

21 January 2018

1 reference

Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice

21 January 2018

1 reference

A potent erythropoietin-mimicking human antibody interacts through a novel binding site

21 January 2018

1 reference

A fully human, allosteric monoclonal antibody that activates the insulin receptor and improves glycemic control

21 January 2018

1 reference

The prevalence of proteolytic antibodies against factor VIII in hemophilia A.

21 January 2018

1 reference

Autoantibodies to factor VIII with catalytic activity.

21 January 2018

1 reference

An antibody specific for coagulation factor IX enhances the activity of the intrinsic factor X-activating complex

21 January 2018

1 reference

A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model

21 January 2018

1 reference

Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A.

21 January 2018

1 reference

Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation

21 January 2018

1 reference

FXIII: mechanisms of action in the treatment of hemophilia A.

21 January 2018

1 reference

Factor XIII combined with recombinant factor VIIa: a new means of treating severe hemophilia A.

21 January 2018

1 reference

Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A.

21 January 2018

1 reference

Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system

21 January 2018

1 reference

Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124).

21 January 2018

1 reference

Aminoglycoside suppression of nonsense mutations in severe hemophilia

21 January 2018

1 reference

A perfect message: RNA surveillance and nonsense-mediated decay

21 January 2018

1 reference

Epsilon-aminocaproic acid inhibits the activity of factor VIII inhibitors in patients with severe haemophilia A in vivo and in vitro.

21 January 2018

1 reference

Role of epsilon amino caproic acid in the management of haemophilic patients with inhibitors

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/HAE.12615

1 reference

1 September 2017

1 reference